xml: <clinical_study>
    <!-- This xml conforms to an XML Schema at:
      https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
    <required_header>
      <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
      <link_text>Link to the current ClinicalTrials.gov record.</link_text>
      <url>https://clinicaltrials.gov/ct2/show/NCT06005220</url>
    </required_header>
    <id_info>
      <org_study_id>SOL-SYNBIOTIC-2023</org_study_id>
      <nct_id>NCT06005220</nct_id>
    </id_info>
    <brief_title>SBD121, a Synbiotic Medical Food for RA Management</brief_title>
    <official_title>A Randomised, Double Blind Placebo-controlled Trial Evaluating the Medical Food Synbiotic SBD121, Versus Placebo for the Clinical Dietary Management of Early Rheumatoid Arthritis.</official_title>
    <sponsors>
      <lead_sponsor>
        <agency>Solarea Bio, Inc</agency>
        <agency_class>Industry</agency_class>
      </lead_sponsor>
    </sponsors>
    <source>Solarea Bio, Inc</source>
    <oversight_info>
      <has_dmc>No</has_dmc>
      <is_fda_regulated_drug>No</is_fda_regulated_drug>
      <is_fda_regulated_device>No</is_fda_regulated_device>
    </oversight_info>
    <brief_summary>
      <textblock>
        The aim of this randomised, double-blind, placebo controlled clinical food trial is to&#xD;
        determine if the medical food SBD121 Synbiotic (prebiotic and probiotic) will aid in the&#xD;
        dietary management of symptoms of early rheumatoid arthritis (RA).&#xD;
      </textblock>
    </brief_summary>
    <overall_status>Not yet recruiting</overall_status>
    <start_date type="Anticipated">September 2023</start_date>
    <completion_date type="Anticipated">September 2024</completion_date>
    <primary_completion_date type="Anticipated">September 2024</primary_completion_date>
    <phase>N/A</phase>
    <study_type>Interventional</study_type>
    <has_expanded_access>No</has_expanded_access>
    <study_design_info>
      <allocation>Randomized</allocation>
      <intervention_model>Parallel Assignment</intervention_model>
      <primary_purpose>Other</primary_purpose>
      <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    </study_design_info>
    <primary_outcome>
      <measure>American College of Rheumatology 20 (ACR-20)</measure>
      <time_frame>16 Weeks</time_frame>
      <description>Evaluate the dietary management of arthritis by the number and percentage of participants achieving American College of Rheumatology 20 (ACR20) response (ie, greater to or equal to 20% improvement in the ACR composite score, a measure of RA symptoms including: joint swelling and tenderness; patient's assessment of pain, arthritis activity, and physical function; physician's assessment of arthritis activity; and CRP) at Week 16</description>
    </primary_outcome>
    <secondary_outcome>
      <measure>Safety by Adverse Events</measure>
      <time_frame>16-weeks</time_frame>
      <description>Number and percentage of participants experiencing adverse events (AEs) and serious adverse events (SAEs)</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Tolerability by GITQ</measure>
      <time_frame>16-weeks</time_frame>
      <description>Frequency and severity of GI symptoms (e.g., gas, abdominal pain, bloating) as assessed by the Gastrointestinal Tolerability Questionnaire (GITQ) score at each timepoint compared to placebo.</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>American College of Rheumatology 20 (ACR-20)</measure>
      <time_frame>8 weeks</time_frame>
      <description>Evaluate the dietary management of arthritis by the number and percentage of participants achieving American College of Rheumatology 20 (ACR20) response (ie, greater to or equal to 20% improvement in the ACR composite score, a measure of RA symptoms including: joint swelling and tenderness; patient's assessment of pain, arthritis activity, and physical function; physician's assessment of arthritis activity; and CRP) at Week 8</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>American College of Rheumatology 50 (ACR-50)</measure>
      <time_frame>8-weeks, 16-weeks</time_frame>
      <description>Evaluate the dietary management of arthritis by the number and percentage of participants achieving ACR50 response in the ACR composite score at Week 8, and Week 16</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>American College of Rheumatology 70 (ACR-70)</measure>
      <time_frame>8-weeks, 16-weeks</time_frame>
      <description>Evaluate the dietary management of arthritis by the number and percentage of participants achieving ACR70 response in the ACR composite score at Week 8, and Week 16</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Disease Activity Score 28 - Eosinophil Sedimentation Rate (DAS28 - ESR)</measure>
      <time_frame>8-weeks, 16-weeks</time_frame>
      <description>Evaluate the dietary management of arthritis by the percentage change from baseline value in the Activity Score-28 (DAS-28) with ESR (DAS-28-ESR), and the individual components that make up the DAS-28-ESR [Tender Joint Count (TJC), Swollen Joint Count (SJC), and Patients Global Assessment of Activity, plus Erythrocyte Sedimentation Rate (ESR)], at 8 and 16 weeks</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Disease Activity Score 28 - C-Reactive Protein (DAS28 - CRP)</measure>
      <time_frame>8-weeks, 16-weeks</time_frame>
      <description>Evaluate the dietary management of arthritis by the percentage change from baseline value in the DAS-28 with CRP score and the individual components that make up the DAS-28 CRP Score [Tender Joint Count (TJC), Swollen Joint Count (SJC), and Patients Global Assessment of Activity, plus C-Reactive Protein (CRP)], at 8 and 16 weeks</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Disease Activity Score 28 - Eosinophil Sedimentation Rate - Low Disease Activity (DAS28 - ESR - LDA)</measure>
      <time_frame>8-weeks, 16-weeks</time_frame>
      <description>Evaluate the dietary management of arthritis by the percentage of participants who achieve DAS-28-ESR Low Activity defined as DAS-28-ESR Score &lt; 3.2, at 8 and 16 weeks</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Disease Activity Score 28 - C-Reactive Protein - Low Disease Activity (DAS28 - CRP LDA)</measure>
      <time_frame>8-weeks, 16-weeks</time_frame>
      <description>Evaluate the dietary management of arthritis by the percentage of participants who achieve DAS-28-CRP Low Activity, defined as DAS-28-CRP Score &lt; 3.2, at 8 and 16 weeks</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Disease Activity Score 28 - Eosinophil Sedimentation Rate - Remission (DAS28 - ESR Remission)</measure>
      <time_frame>8-weeks, 16-weeks</time_frame>
      <description>Evaluate the dietary management of arthritis by the percentage of participants who achieve DAS-28-ESR Remission defined as DAS-28-ESR Score &lt; 2.6, at 8 and 16 weeks</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Disease Activity Score 28 - C-Reactive Protein - Remission (DAS28 - CRP Remission)</measure>
      <time_frame>8-weeks, 16-weeks</time_frame>
      <description>Evaluate the dietary management of arthritis by the percentage of participants who achieve DAS-28-CRP Remission, defined as DAS-28-CRP Score &lt; 2.6, at 8 and 16 weeks</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>C-Reactive Protein (CRP)</measure>
      <time_frame>8-weeks, 16-weeks</time_frame>
      <description>Evaluate the dietary management of arthritis by the improvement in CRP from baseline</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Eosinophil Sedimentation Rate (ESR)</measure>
      <time_frame>8-weeks, 16-weeks</time_frame>
      <description>Evaluate the dietary management of arthritis by the improvement in ESR from baseline</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Zonulin</measure>
      <time_frame>8-weeks, 16-weeks</time_frame>
      <description>Evaluate improvement in gastrointestinal permeability by improvement in Zonulin from baseline</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Reduce or discontinue use of oral corticosteroids</measure>
      <time_frame>8-weeks, 16-weeks</time_frame>
      <description>Evaluate the dietary management of arthritis by the number and percentage of participants able to reduce dose or discontinue use of oral corticosteroids, at 8 and 16 weeks</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Reduce or discontinue use of oral NSAIDs</measure>
      <time_frame>8-weeks, 16-weeks</time_frame>
      <description>Evaluate the dietary management of arthritis by the number and percentage of participants able to reduce dose or discontinue use of oral NSAIDs, at 8 and 16 weeks</description>
    </secondary_outcome>
    <other_outcome>
      <measure>Microbiome functional composition by shotgun metagenomics</measure>
      <time_frame>16-weeks</time_frame>
      <description>Change in the functional gut microbiota composition in stool samples from baseline and correlation with primary and secondary efficacy outcomes, at 16 weeks</description>
    </other_outcome>
    <other_outcome>
      <measure>Microbiome taxonomic composition by shotgun metagenomics</measure>
      <time_frame>16-weeks</time_frame>
      <description>Change in the taxonomic gut microbiota composition in stool samples from baseline and correlation with primary and secondary efficacy outcomes, at 16 weeks</description>
    </other_outcome>
    <number_of_arms>2</number_of_arms>
    <enrollment type="Anticipated">140</enrollment>
    <condition>Rheumatoid Arthritis</condition>
    <arm_group>
      <arm_group_label>SBD121 Medical Food</arm_group_label>
      <arm_group_type>Active Comparator</arm_group_type>
      <description>Two capsules administered twice daily with food</description>
    </arm_group>
    <arm_group>
      <arm_group_label>Placebo</arm_group_label>
      <arm_group_type>Placebo Comparator</arm_group_type>
      <description>Two capsules administered twice daily with food</description>
    </arm_group>
    <intervention>
      <intervention_type>Other</intervention_type>
      <intervention_name>SBD121</intervention_name>
      <description>Medical Food</description>
      <arm_group_label>SBD121 Medical Food</arm_group_label>
    </intervention>
    <intervention>
      <intervention_type>Other</intervention_type>
      <intervention_name>Placebo</intervention_name>
      <description>Placebo</description>
      <arm_group_label>Placebo</arm_group_label>
    </intervention>
    <eligibility>
      <criteria>
        <textblock>
          Inclusion Criteria:&#xD;
  &#xD;
            1. Willing and able to provide written informed consent prior to the performance of any&#xD;
               study-specific procedure and willing to comply with the protocol and report on&#xD;
               compliance and side effects during study period.&#xD;
  &#xD;
            2. Male or female aged 18 - 70 years inclusive at the time of consent.&#xD;
  &#xD;
            3. The participant must have newly diagnosed RA, not exceeding 1-year from diagnosis&#xD;
  &#xD;
            4. The participant must have been taking methotrexate (MTX) for treatment of RA for ≤&#xD;
               1-month before baseline, or will be commencing MTX at the same time as baseline.&#xD;
  &#xD;
            5. The participant must have active RA meeting classification criteria according to the&#xD;
               2010 ACR/EULAR guidelines with a score equal to or greater than 6/10 at screening&#xD;
               (11). (Seropositivity is not required).&#xD;
  &#xD;
            6. The participant must be available throughout entire study period, willing and able to&#xD;
               attend all scheduled visits and in the opinion of the Investigator be able to&#xD;
               understand and comply with planned study procedures.&#xD;
  &#xD;
            7. Body Mass Index (BMI) between 18.5 and 35 kg/m2&#xD;
  &#xD;
            8. Normal cardiovascular parameters (systolic blood pressure ≤ 150 mm Hg, diastolic blood&#xD;
               pressure ≤ 90 mm Hg). One re-test is permitted.&#xD;
  &#xD;
            9. Women of childbearing potential must have a negative serum pregnancy test at screening&#xD;
               and negative urine pregnancy test pre-first administration, on Day 1, and must agree&#xD;
               to remain sexually abstinent, or use medically effective contraception (refer to&#xD;
               Appendix 11.1), or have a partner who is sterile or same-sex, from Screening until end&#xD;
               of study. Males must not be planning to father children or donate sperm for the&#xD;
               duration of the study.&#xD;
  &#xD;
          Exclusion Criteria:&#xD;
  &#xD;
            1. Participant is currently taking any probiotic or prebiotic supplements, or has taken&#xD;
               them in the past 30 days, or is unwilling to avoid taking probiotic/prebiotic&#xD;
               supplements for the duration of the study.&#xD;
  &#xD;
            2. Participant has any known or suspected allergies to probiotics or prebiotics.&#xD;
  &#xD;
            3. Participant has taken oral or parenteral antibiotics within 3-months of screening,&#xD;
               requires antibiotics pre-first dose, or is likely to require antibiotics during the&#xD;
               study period.&#xD;
  &#xD;
            4. Participant has undergone major surgery or endoscopy within last 3-months before&#xD;
               screening or planned during the study period&#xD;
  &#xD;
            5. Participant is a current smoker and/or uses nicotine replacement therapies (including&#xD;
               vaping).&#xD;
  &#xD;
            6. Participant has a past or current history of drug and/or alcohol abuse at the time of&#xD;
               enrolment (the use of illegal drugs or the use of prescription or over-the-counter&#xD;
               drugs or alcohol for purposes other than those for which they are meant to be used, or&#xD;
               in excessive amounts).&#xD;
  &#xD;
            7. Participant has a known history of any of the following (according to Investigator&#xD;
               judgement and/or participant report):&#xD;
  &#xD;
                 1. Gastric or intestinal dysmotility, slowed transit time, pancreatitis, or&#xD;
                    inflammatory bowel disease&#xD;
  &#xD;
                 2. Known Hepatitis B or Hepatitis C infection, cirrhosis or chronic liver disease&#xD;
  &#xD;
                 3. Underlying structural heart disease or previous history of endocarditis or valve&#xD;
                    replacement&#xD;
  &#xD;
                 4. Rheumatic disease other than rheumatoid arthritis, including but not limited to&#xD;
                    psoriasis, spondyloarthritis, systemic lupus erythematosus, multiple sclerosis&#xD;
  &#xD;
                 5. Immunosuppressed, including: known HIV positive; solid organ or stem cell&#xD;
                    transplant recipient; taking any oral or parenteral immunosuppressive therapy;&#xD;
                    neutrophil count &lt;500/mm3; or anticipated drop in the neutrophil count to&#xD;
                    &lt;500/mm3&#xD;
  &#xD;
                 6. Any malignancy, with the exception of non-melanoma skin cancers, or other cancer&#xD;
                    more than 5-years ago&#xD;
  &#xD;
                 7. Active tuberculosis (TB) within 3-months prior to Screening&#xD;
  &#xD;
                 8. Any infection requiring hospitalisation, parental antimicrobial therapy, or as&#xD;
                    otherwise judged clinically significant, within 3-months prior to Screening&#xD;
  &#xD;
            8. Presence of any of the following active conditions at Screening, or within 72 hours of&#xD;
               the first administration of study test article:&#xD;
  &#xD;
                 1. Clinically significant abnormal vital signs or physical examination abnormalities&#xD;
                    (other than those related to RA, such as joint swelling)&#xD;
  &#xD;
                 2. Febrile illness (oral temp. &gt; 37 degrees Celsius), or one or more episodes of&#xD;
                    diarrhoea within 72 hours of the first dose of study test article&#xD;
  &#xD;
                 3. Acute abdomen, colitis, or active GI disease&#xD;
  &#xD;
                 4. Septicaemia or bacteraemia&#xD;
  &#xD;
                 5. Uncontrolled diabetes mellitus, based on medical history and in response to query&#xD;
                    'is your diabetes under control?'.&#xD;
  &#xD;
            9. Current treatment with any Disease Modifying Arthritis Drug (DMARD) other than&#xD;
               methotrexate including but not limited to, hydroxychloroquine, sulfasalazine, and&#xD;
               minocycline leflunomide, gold compounds, azathioprine, or cyclosporine will be&#xD;
               exclusionary if used within 1-month prior to randomisation.&#xD;
  &#xD;
           10. Current or past treatment with any biologic agent including but not limited to tumor&#xD;
               necrosis factor (TNF) inhibitors: etanercept, infliximab, adalimumab; interleukin 1&#xD;
               (IL-1) inhibitors: anakinra; lymphocyte directed: abatacept, rituximab; Janus kinase&#xD;
               (JAK) inhibitors: tofacitinib; interleukin 17 (IL-17) inhibitors; Interleukin 23&#xD;
               (IL-23) inhibitors.&#xD;
  &#xD;
           11. Corticosteroid use from 1-month prior to randomisation until final assessment visit&#xD;
               will be exclusionary, with the following exceptions:&#xD;
  &#xD;
                 1. Oral corticosteroids in low doses (≤ 10 mg/d prednisone or equivalent) will be&#xD;
                    allowed if stable for 1-month prior to randomisation. Reduction of dose or use of&#xD;
                    oral corticosteroids is permissible throughout the study.&#xD;
  &#xD;
                 2. Topical, inhaled, or intranasal steroids are permitted&#xD;
  &#xD;
                 3. Past use of oral or parenteral (&gt; 10 mg/d prednisone or equivalent)&#xD;
                    corticosteroids is allowed if not used within 1-month prior to randomisation.&#xD;
  &#xD;
           12. Women only - pregnant, planning on becoming pregnant during the trial, breastfeeding,&#xD;
               positive urine pregnancy test during Screening or within 24 hours of first&#xD;
               administration of study test article.&#xD;
  &#xD;
           13. Any of the following abnormal findings on Screening or Baseline laboratory tests (one&#xD;
               re-test per timepoint permitted):&#xD;
  &#xD;
                 1. white blood cells (WBCs) &lt; lower limit of normal (LLN) or &gt; upper limit of normal&#xD;
                    (ULN)&#xD;
  &#xD;
                 2. Neutrophils &lt; 1500/µl (1.5 x109/L)&#xD;
  &#xD;
                 3. Platelets &lt; 100 x 10³/µl (100 x 109/L)&#xD;
  &#xD;
                 4. Haemoglobin &lt; 9.0 g/dl (90 g/L)&#xD;
  &#xD;
                 5. Serum Creatinine &gt; 1.5 x ULN&#xD;
  &#xD;
                 6. Glomerular filtration rate (GFR) of &gt; 40 mL/minute&#xD;
  &#xD;
                 7. Aspartate aminotransferase (AST) &gt; 3 x ULN&#xD;
  &#xD;
                 8. Alanine aminotransferase (ALT) &gt; 3 x ULN&#xD;
  &#xD;
                 9. Total Bilirubin &gt; 1.5 x ULN&#xD;
  &#xD;
           14. Any other condition that in the opinion of the investigator would jeopardize the&#xD;
               safety or rights of the volunteer participating in the study or would make it unlikely&#xD;
               the volunteer could complete the study&#xD;
  &#xD;
           15. If the participant has been in a recent experimental trial, these must have been&#xD;
               completed not less than 60 days prior to this study.&#xD;
        </textblock>
      </criteria>
      <gender>All</gender>
      <minimum_age>18 Years</minimum_age>
      <maximum_age>70 Years</maximum_age>
      <healthy_volunteers>No</healthy_volunteers>
    </eligibility>
    <overall_official>
      <last_name>Maureen Stanley</last_name>
      <role>Study Director</role>
      <affiliation>Southern Star Research Pty Ltd.</affiliation>
    </overall_official>
    <overall_contact>
      <last_name>Eric Schott</last_name>
      <phone>585-704-8069</phone>
      <email>eschott@solareabio.com</email>
    </overall_contact>
    <verification_date>September 2023</verification_date>
    <study_first_submitted>August 7, 2023</study_first_submitted>
    <study_first_submitted_qc>August 16, 2023</study_first_submitted_qc>
    <study_first_posted type="Actual">August 22, 2023</study_first_posted>
    <last_update_submitted>September 6, 2023</last_update_submitted>
    <last_update_submitted_qc>September 6, 2023</last_update_submitted_qc>
    <last_update_posted type="Actual">September 8, 2023</last_update_posted>
    <responsible_party>
      <responsible_party_type>Sponsor</responsible_party_type>
    </responsible_party>
    <condition_browse>
      <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
      <mesh_term>Arthritis</mesh_term>
      <mesh_term>Arthritis, Rheumatoid</mesh_term>
    </condition_browse>
    <patient_data>
      <sharing_ipd>No</sharing_ipd>
    </patient_data>
    <!-- Results have not yet been posted for this study                                          -->
  </clinical_study>
  
  
text: download date: ClinicalTrials.gov processed this data on September 20, 2023
  link text: Link to the current ClinicalTrials.gov record.
  url: https://clinicaltrials.gov/ct2/show/NCT06005220
  org study id: SOL-SYNBIOTIC-2023
  nct id: NCT06005220
  lead sponsor: 
  has dmc: No
  is fda regulated drug: No
  is fda regulated device: No
  The aim of this randomised, double-blind, placebo controlled clinical food trial is to
        determine if the medical food SBD121 Synbiotic (prebiotic and probiotic) will aid in the
        dietary management of symptoms of early rheumatoid arthritis (RA).
  allocation: Randomized
  intervention model: Parallel Assignment
  primary purpose: Other
  masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
  measure: American College of Rheumatology 20 (ACR-20)
  time frame: 16 Weeks
  description: Evaluate the dietary management of arthritis by the number and percentage of participants achieving American College of Rheumatology 20 (ACR20) response (ie, greater to or equal to 20% improvement in the ACR composite score, a measure of RA symptoms including: joint swelling and tenderness; patient's assessment of pain, arthritis activity, and physical function; physician's assessment of arthritis activity; and CRP) at Week 16
  measure: Safety by Adverse Events
  time frame: 16-weeks
  description: Number and percentage of participants experiencing adverse events (AEs) and serious adverse events (SAEs)
  measure: Tolerability by GITQ
  time frame: 16-weeks
  description: Frequency and severity of GI symptoms (e.g., gas, abdominal pain, bloating) as assessed by the Gastrointestinal Tolerability Questionnaire (GITQ) score at each timepoint compared to placebo.
  measure: American College of Rheumatology 20 (ACR-20)
  time frame: 8 weeks
  description: Evaluate the dietary management of arthritis by the number and percentage of participants achieving American College of Rheumatology 20 (ACR20) response (ie, greater to or equal to 20% improvement in the ACR composite score, a measure of RA symptoms including: joint swelling and tenderness; patient's assessment of pain, arthritis activity, and physical function; physician's assessment of arthritis activity; and CRP) at Week 8
  measure: American College of Rheumatology 50 (ACR-50)
  time frame: 8-weeks, 16-weeks
  description: Evaluate the dietary management of arthritis by the number and percentage of participants achieving ACR50 response in the ACR composite score at Week 8, and Week 16
  measure: American College of Rheumatology 70 (ACR-70)
  time frame: 8-weeks, 16-weeks
  description: Evaluate the dietary management of arthritis by the number and percentage of participants achieving ACR70 response in the ACR composite score at Week 8, and Week 16
  measure: Disease Activity Score 28 - Eosinophil Sedimentation Rate (DAS28 - ESR)
  time frame: 8-weeks, 16-weeks
  description: Evaluate the dietary management of arthritis by the percentage change from baseline value in the Activity Score-28 (DAS-28) with ESR (DAS-28-ESR), and the individual components that make up the DAS-28-ESR [Tender Joint Count (TJC), Swollen Joint Count (SJC), and Patients Global Assessment of Activity, plus Erythrocyte Sedimentation Rate (ESR)], at 8 and 16 weeks
  measure: Disease Activity Score 28 - C-Reactive Protein (DAS28 - CRP)
  time frame: 8-weeks, 16-weeks
  description: Evaluate the dietary management of arthritis by the percentage change from baseline value in the DAS-28 with CRP score and the individual components that make up the DAS-28 CRP Score [Tender Joint Count (TJC), Swollen Joint Count (SJC), and Patients Global Assessment of Activity, plus C-Reactive Protein (CRP)], at 8 and 16 weeks
  measure: Disease Activity Score 28 - Eosinophil Sedimentation Rate - Low Disease Activity (DAS28 - ESR - LDA)
  time frame: 8-weeks, 16-weeks
  description: Evaluate the dietary management of arthritis by the percentage of participants who achieve DAS-28-ESR Low Activity defined as DAS-28-ESR Score < 3.2, at 8 and 16 weeks
  measure: Disease Activity Score 28 - C-Reactive Protein - Low Disease Activity (DAS28 - CRP LDA)
  time frame: 8-weeks, 16-weeks
  description: Evaluate the dietary management of arthritis by the percentage of participants who achieve DAS-28-CRP Low Activity, defined as DAS-28-CRP Score < 3.2, at 8 and 16 weeks
  measure: Disease Activity Score 28 - Eosinophil Sedimentation Rate - Remission (DAS28 - ESR Remission)
  time frame: 8-weeks, 16-weeks
  description: Evaluate the dietary management of arthritis by the percentage of participants who achieve DAS-28-ESR Remission defined as DAS-28-ESR Score < 2.6, at 8 and 16 weeks
  measure: Disease Activity Score 28 - C-Reactive Protein - Remission (DAS28 - CRP Remission)
  time frame: 8-weeks, 16-weeks
  description: Evaluate the dietary management of arthritis by the percentage of participants who achieve DAS-28-CRP Remission, defined as DAS-28-CRP Score < 2.6, at 8 and 16 weeks
  measure: C-Reactive Protein (CRP)
  time frame: 8-weeks, 16-weeks
  description: Evaluate the dietary management of arthritis by the improvement in CRP from baseline
  measure: Eosinophil Sedimentation Rate (ESR)
  time frame: 8-weeks, 16-weeks
  description: Evaluate the dietary management of arthritis by the improvement in ESR from baseline
  measure: Zonulin
  time frame: 8-weeks, 16-weeks
  description: Evaluate improvement in gastrointestinal permeability by improvement in Zonulin from baseline
  measure: Reduce or discontinue use of oral corticosteroids
  time frame: 8-weeks, 16-weeks
  description: Evaluate the dietary management of arthritis by the number and percentage of participants able to reduce dose or discontinue use of oral corticosteroids, at 8 and 16 weeks
  measure: Reduce or discontinue use of oral NSAIDs
  time frame: 8-weeks, 16-weeks
  description: Evaluate the dietary management of arthritis by the number and percentage of participants able to reduce dose or discontinue use of oral NSAIDs, at 8 and 16 weeks
  measure: Microbiome functional composition by shotgun metagenomics
  time frame: 16-weeks
  description: Change in the functional gut microbiota composition in stool samples from baseline and correlation with primary and secondary efficacy outcomes, at 16 weeks
  measure: Microbiome taxonomic composition by shotgun metagenomics
  time frame: 16-weeks
  description: Change in the taxonomic gut microbiota composition in stool samples from baseline and correlation with primary and secondary efficacy outcomes, at 16 weeks
  arm group label: SBD121 Medical Food
  arm group type: Active Comparator
  description: Two capsules administered twice daily with food
  arm group label: Placebo
  arm group type: Placebo Comparator
  description: Two capsules administered twice daily with food
  intervention type: Other
  intervention name: SBD121
  description: Medical Food
  arm group label: SBD121 Medical Food
  intervention type: Other
  intervention name: Placebo
  description: Placebo
  arm group label: Placebo
  criteria: 
  gender: All
  minimum age: 18 Years
  maximum age: 70 Years
  healthy volunteers: No
  last name: Maureen Stanley
  role: Study Director
  affiliation: Southern Star Research Pty Ltd.
  last name: Eric Schott
  phone: 585-704-8069
  email: eschott@solareabio.com
  responsible party type: Sponsor
  mesh term: Arthritis
  mesh term: Arthritis, Rheumatoid
  sharing ipd: No